FindTrial
Sign In

Influence of suplementation of different types of fats on heart health.

LDL and HDL physical and chemical properties, oxidative and cardiometabolic biomarkers may be modulated by consumption of omega-3, omega-6 and omega-9 in individuals with intermediate cardiovascular risk?

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-2vfhfv
Enrollment
Unknown
Registered
2016-05-27
Start date
2011-08-15
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular diseases, unspecified Hyperlipemia, Non-insulin-dependent diabetes mellitus, Essential (primary) hypertension , Obesity.

Interventions

Randomized double blind study 4 interventions: omega 3 (n=90)- fish oil (EPA e DHA fatty acid 60%), 3 capsules per day, 1.0 g/capsule). omega 6 (n=90)- linoleic fatty acid 65%.3 capsules per day, 1.0
Dietary supplement
D10.212.302.380.410
D10.251.355.343
J02.500.456

Sponsors

Faculdade de Saúde Pública da Universidade de São Paulo
Lead Sponsor
Hospital Universitário da Universidade de São Paulo
Collaborator

Eligibility

Age
30 Years to 74 Years

Inclusion criteria

Inclusion criteria: Both sexes, between 30 to 74 years old, medium and high cardiovascular risk.

Exclusion criteria

Exclusion criteria: Malnutrition, prengnancy, previous cardiovascular event, included in other clinical trial, using ilegal drugs, psychiatric alterations, allergic to any compound of intervention.

Design outcomes

Primary

MeasureTime frame
The omega 3 intervention will promote, in comparison to other fatty acids and placebo: Reduction of electronegative LDL, LDL(-); Reduction of small LDL subfraction and increase of large LDL subfraction; Reduction of small HDL subfraction and increase of large HDL subfraction; Increase of paroxonase (PON1); Reduction of non esterified fatty acid (NEFAs).;The omega 3 intervention promoted, in comparison to other fatty acids and placebo: Reduction of electronegative LDL, LDL(-) (-21%); Reduction of small LDL subfraction (-1.7%) and increase of large LDL subfraction (3.0 nm); Reduction of small HDL subfraction (-2.5%) and increase of large HDL subfraction (4.0%); Increase of paroxonase (PON1) (1.2%); Reduction of non esterified fatty acid (NEFAs) (-0.1%).—

Secondary

MeasureTime frame
The omega 3 intervention will promote, in comparison to other fatty acids and placebo: Improve of lipid profile; Improve of anthropometric parameters; Improve in glucose; Improve in blood pressure;;The omega 3 intervention promoted, in comparison to other fatty acids and placebo: Improve of lipid profile (-12% CT, -13.4% LDL-c, -23% TAG and +7.9% HDL-c). Improve of anthropometric parameters (-0.5 % body fat); Improve in blood pressure (-3.6 SBP e -4.7 DBP).—

Countries

Brazil

Contacts

Public ContactNágila Raquel Damasceno

Faculdade de Saúde Pública da Universidade de São Paulo

nagila@usp.br+55 11 30617865

Outcome results

None listed

Source: REBEC (via WHO ICTRP)